Teduglutide: all 35 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• TED_ORG: Study on Short Bowel SyndromeRecruitingNCT07400783Not applicable
• A Study of Teduglutide in Japanese Children With Short Bowel Syndrome Aged 4 Months or OlderCompletedNCT05027308Phase 3Results posted
• A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult ParticipantsCompletedNCT04465396Phase 1Results posted
• Study of Teduglutide in Japanese Participants With Short Bowel SyndromeCompletedNCT03663582Phase 3Results posted
• An Extension Study of Teduglutide in Japanese Participants With Short Bowel Syndrome Who Completed 24 Weeks of Treatment in SHP633-306 or TED-C14-004CompletedNCT03596164Phase 3Results posted
• Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel SyndromeCompletedNCT03571516Phase 3Results posted
• A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302CompletedNCT03268811Phase 3Results posted
• Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral SupportCompletedNCT02980666Phase 3Results posted
• Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 StudyCompletedNCT02949362Phase 3Results posted
• Teduglutide for Enterocutaneous Fistula (ECF)CompletedNCT02889393Phase 2Results posted
• Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral NutritionCompletedNCT02682381Phase 3Results posted
• A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIVCompletedNCT02431325Phase 2Results posted
• Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)CompletedNCT02340819Phase 3Results posted
• Short Bowel Syndrome and Teduglutide Versus PlaceboCompletedNCT02099084Phase 4Results posted
• A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel SyndromeCompletedNCT01952080Phase 3Results posted
• A One-Year, Open-Label Study With Teduglutide for Subjects Who Completed Study CL0600-021CompletedNCT01560403Phase 3Results posted
• Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)CompletedNCT00930644Phase 3Results posted
• Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) SubjectsCompletedNCT00798967Phase 3Results posted
• Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)CompletedNCT00172185Phase 3Results posted
• Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel SyndromeCompletedNCT00081458Phase 3Results posted
• A Study of Teduglutide in Chinese Adults With Short Bowel SyndromeActive, not recruitingNCT06973304Phase 3
• Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD PatientsCompletedNCT04290429Early Phase 1
• Pilot Study to Investigate the Effect of Teduglutide on Temporary Ileostomy Function and ComplicationsWithdrawnNCT03953170Phase 3
• Therapeutic Approaches to Malnutrition EnteropathyCompletedNCT03716115Phase 2
• Characterization of the Long-term Safety, Efficacy, and Pharmacodynamics Revestive® in the Management of Short Bowel Syndrome Pediatric PatientsCompletedNCT03562130Phase 4
• L-NMMA on GLP-2 Mediated Intestinal Lipoprotein ReleaseCompletedNCT03534661Phase 2/3
• Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral LipidsCompletedNCT03442972Phase 2/3
• Plasma Lipoprotein Response to Glucagon-like Peptide-2CompletedNCT03422666Phase 2/3
• Effect of Teduglutide on Gastric Emptying in Healthy SubjectsCompletedNCT01209351Phase 1
• Effects of Teduglutide on Cardiac Repolarisation and Conduction in Healthy Male and Female VolunteersCompletedNCT01028924Phase 1
• Pharmacokinetics of 10 mg Teduglutide in Subjects With Renal Impairment Compared to Healthy Subjects With Normal Renal FunctionCompletedNCT01028768Phase 1
• A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of TeduglutideCompletedNCT00820885Phase 1
• Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy ParticipantsCompletedNCT00819468Phase 1
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease Who Completed Protocol CL0600-008CompletedNCT00308438Phase 2
• Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's DiseaseCompletedNCT00072839Phase 2

← Teduglutide overview